S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
Log in
NASDAQ:OCUP

Ocuphire Pharma Stock Forecast, Price & News

$9.36
+0.01 (+0.11 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$8.51
Now: $9.36
$9.48
50-Day Range
$6.96
MA: $10.77
$13.31
52-Week Range
$3.68
Now: $9.36
$14.80
Volume97,344 shs
Average Volume104,238 shs
Market Capitalization$101.86 million
P/E RatioN/A
Dividend YieldN/A
Beta0.76
Ocuphire Pharma, Inc. engages in the research and development of ophthalmic biopharmaceutical products. It focuses on developing and commercializing therapies for the treatment of several eye disorders. The company was founded by Mina Patel Soouch and Alan R. Meyer in February 2018 and is headquartered in Farmington Hills, MI.

Headlines

Ocuphire to Participate in March Investor Conferences
March 4, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:OCUP
CUSIPN/A
CIKN/A
Phone(248) 681-9815
Employees4
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$9.91 per share

Profitability

Net Income$-8,640,000.00

Miscellaneous

Market Cap$101.86 million
Next Earnings DateN/A
OptionableNot Optionable

MarketRank

Overall MarketRank

1.99 out of 5 stars

Medical Sector

73rd out of 1,972 stocks

Pharmaceutical Preparations Industry

27th out of 772 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
$9.36
+0.01 (+0.11 %)
(As of 03/5/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive OCUP News and Ratings via Email

Sign-up to receive the latest news and ratings for OCUP and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Ocuphire Pharma (NASDAQ:OCUP) Frequently Asked Questions

Is Ocuphire Pharma a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ocuphire Pharma in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Ocuphire Pharma stock.
View analyst ratings for Ocuphire Pharma
or view top-rated stocks.

What stocks does MarketBeat like better than Ocuphire Pharma?

Wall Street analysts have given Ocuphire Pharma a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Ocuphire Pharma wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Ocuphire Pharma?

Ocuphire Pharma saw a decline in short interest during the month of February. As of February 12th, there was short interest totaling 8,000 shares, a decline of 67.6% from the January 28th total of 24,700 shares. Based on an average trading volume of 87,500 shares, the short-interest ratio is presently 0.1 days. Currently, 0.1% of the shares of the stock are short sold.
View Ocuphire Pharma's Short Interest
.

What price target have analysts set for OCUP?

2 analysts have issued twelve-month target prices for Ocuphire Pharma's stock. Their forecasts range from $15.00 to $22.00. On average, they anticipate Ocuphire Pharma's stock price to reach $18.50 in the next year. This suggests a possible upside of 97.6% from the stock's current price.
View analysts' price targets for Ocuphire Pharma
or view top-rated stocks among Wall Street analysts.

Who are Ocuphire Pharma's key executives?

Ocuphire Pharma's management team includes the following people:
  • Mina Patel Sooch, President, Chief Executive Officer & Director
  • Bernhard Hoffmann, Vice President-Corporate Development & Operations
  • Amy Rabourn, Chief Accounting Officer & Vice President-Finance
  • Konstantinos Charizanis, Senior Director-Market Strategy, R&D
  • Drey Coleman, Director-Clinical Operations & Vendor Management

Who are some of Ocuphire Pharma's key competitors?

What is Ocuphire Pharma's stock symbol?

Ocuphire Pharma trades on the NASDAQ under the ticker symbol "OCUP."

Who are Ocuphire Pharma's major shareholders?

Ocuphire Pharma's stock is owned by a variety of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (6.59%), Comerica Bank (2.68%) and Squarepoint Ops LLC (0.18%).

Which major investors are buying Ocuphire Pharma stock?

OCUP stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Comerica Bank, and Squarepoint Ops LLC.

How do I buy shares of Ocuphire Pharma?

Shares of OCUP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ocuphire Pharma's stock price today?

One share of OCUP stock can currently be purchased for approximately $9.36.

How much money does Ocuphire Pharma make?

Ocuphire Pharma has a market capitalization of $101.86 million.

How many employees does Ocuphire Pharma have?

Ocuphire Pharma employs 4 workers across the globe.

What is Ocuphire Pharma's official website?

The official website for Ocuphire Pharma is www.ocuphire.com.

Where are Ocuphire Pharma's headquarters?

Ocuphire Pharma is headquartered at 15245 SHADY GROVE ROAD SUITE 455, ROCKVILLE MD, 20850.

How can I contact Ocuphire Pharma?

Ocuphire Pharma's mailing address is 15245 SHADY GROVE ROAD SUITE 455, ROCKVILLE MD, 20850. The company can be reached via phone at (248) 681-9815 or via email at [email protected]


This page was last updated on 3/6/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.